Ovarian Cancer Slowed by Drug Conjugate (DMUC5754A)

Medpage

Action Points

• Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
• More than 20% of selected patients with platinum-resistant ovarian cancer had objective responses to an antibody-drug conjugate (DMUC5754A) targeting a protein common to most ovarian tumors.
• Note that DMUC5754A was well tolerated, most adverse events were grade 1/2 severity, and fatigue was the most common grade 3/4 adverse event.